Target intelligence / Profile preview

Ribosomal protein S28 pseudogene

Molecular classification
Other (pseudogene)
01

Overview

Ribosomal protein S28 pseudogenes are non-coding genomic loci derived from the parental ribosomal protein S28 gene via duplication or retrotransposition. They do not produce functional protein products, but accumulating evidence suggests their long non-coding RNAs may act as competitive endogenous RNAs (ceRNAs), binding and sequestering microRNAs that would otherwise regulate the parental RPS28 gene. For example, increased expression of some ribosomal protein S28 pseudogenes (e.g., RPS28P7) has been associated with cancer progression, likely by up-regulating the parental RPS28 protein via miRNA sponging. These pseudogenes are not considered traditional drug targets, but emerging research proposes their RNA may represent a novel class of regulatory molecules and possible biomarkers or experimental RNA therapeutic targets in some cancers. This entry is not a protein-coding ribosomal subunit or traditional therapeutic target. If you are seeking information on the functional protein (ribosomal protein S28, gene symbol RPS28), refer instead to RPS28/ENSG00000233927. The "ribosomal protein S28 pseudogene" refers to one of several pseudogenes, not to an active molecular target.

02

Mechanism of action

None established. A hypothetical approach is using small molecules or RNA therapies to degrade the pseudogene transcript to modulate miRNA regulation of parental protein-coding genes.

03

Biological functions

Other (as a pseudogene, it does not directly encode a protein with cellular function; however, emerging evidence suggests some ribosomal pseudogene transcripts may regulate their parent genes via competitive endogenous RNA [ceRNA] mechanisms)
04

Disease associations

Other. There is some preliminary evidence linking RPS28 pseudogene expression (e.g., RPS28P7) to cancer prognosis, particularly aggressive behavior in pancreatic cancer and other malignancies, possibly via regulatory ceRNA sponging that increases parental RPS28 gene expression. However, this is not yet well-established or clinically actionable.
05

Safety considerations

None specific. Any therapy targeting a pseudogene would have risks associated with off-target RNA modulation, but there are no direct safety data since no such drugs exist.
06

Biomarkers

Up-regulation of specific ribosomal protein S28 pseudogenes (e.g., RPS28P7) has been proposed as a prognostic biomarker for poor survival in pancreatic cancer and other tumors in experimental research, but this is not widely validated.

Beyond the preview

Go deeper on Ribosomal protein S28 pseudogene.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein S28 pseudogene.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call